Evidence map›Paper›PMID 33602116›Full record

ArticleClinical proteomics2021

Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients.

Tineke E Buffart, Rosanne A H M van den Oord, Adriënne van den Berg, Riet Hilhorst, Niek Bastiaensen, Hans F M Pruijt, Adriaan van den Brule, Peet Nooijen, Mariette Labots, Richard R de Goeij-de Haas and 8 more

Open access · goldAbstract read
In one paragraph

Article in Clinical proteomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Tineke E BuffartDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Rosanne A H M van den OordDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Adriënne van den BergPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Riet HilhorstPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Niek BastiaensenPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Hans F M PruijtDepartment of Medical Oncology, Jeroen Bosch Hospital, 'S-Hertogenbosch, The Netherlands.
Adriaan van den BruleLaboratory of Molecular Diagnostics, Jeroen Bosch Hospital, 'S-Hertogenbosch, The Netherlands.
Peet NooijenDepartment of Pathology, Jeroen Bosch Hospital, 'S-Hertogenbosch, The Netherlands.
Mariette LabotsDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Richard R de Goeij-de HaasDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Henk DekkerDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Sander R PiersmaDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Thang V PhamDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Theo van der LeijPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Rik de WijnPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Rob RuijtenbeekPamGene International BV, 'S-Hertogenbosch, The Netherlands.
Connie R JiménezDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Henk M W VerheulDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. Henk.verheul@radboudumc.nl.ORCID http://orcid.org/0000-0001-5981-922X
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLPamGene (Netherlands) · NLJeroen Bosch Ziekenhuis · NLGenmab (Netherlands) · NLRadboud University Nijmegen · NLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on their potential to analyze aberrant cellular signaling in relation to biological function, kinase activity profiling in tumor biopsies by peptide microarrays and mass spectrometry-based phosphoproteomics may guide selection of protein kinase inhibitors in patients with cancer. Variable tissue handling procedures in clinical practice may influence protein phosphorylation status and kinase activity and therewith may hamper biomarker discovery. Here, the effect of cold ischemia time (CIT) on the stability of kinase activity and protein phosphorylation status in fresh-frozen clinical tissue samples was studied using peptide microarrays and mass spectrometry-based phosphoproteomics.

methodsBiopsies of colorectal cancer resection specimens from five patients were collected and snap frozen immediately after surgery and at 6 additional time points between 0 and 180 min of CIT. Kinase activity profiling was performed for all samples using a peptide microarray. MS-based global phosphoproteomics was performed in tumors from 3 patients at 4 time points. Statistical and cluster analyses were performed to analyze changes in kinase activity and phosphoproteome resulting from CIT.

resultsUnsupervised cluster analysis of kinase activity and phosphoproteome data revealed that samples from the same patients cluster together. Continuous ANOVA analysis of all 7 time points for 5 patient samples resulted in 4 peptides out of 210 (2%) with significantly (p < 0.01 and fold change > 2) altered signal intensity in time. In 4 out of 5 patients tumor kinase activity was stable with CIT. MS-based phosphoproteomics resulted in the detection of 10,488 different phosphopeptides with on average 6044 phosphopeptides per tumor sample. 2715 phosphopeptides were detected in all samples at time point 0, of which 90 (3.3%) phosphopeptides showed significant changes in intensity with CIT (p < 0.01). Only two phosphopeptides were significantly changed in all time points, including one peptide (PKP3) with a fold change > 2.

conclusionsThe vast majority of the phosphoproteome as well as the activity of protein kinases in colorectal cancer resection tissue is stable up to 180 min of CIT and reflects tumor characteristics. However, specific changes in kinase activity with increasing CIT were observed. Therefore, stringent tissue collection procedures are advised to minimize changes in kinase activity during CIT.

Indexed as

CancerCold ischemiaMass spectrometryPeptide microarrayPhosphoproteomicsProtein kinase

Identifiers

PMID33602116
PMCPMC7893972
OpenAlexW3133196932

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.